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Background: Essential tremor (ET) is one of the most common neurological diseases.
Although a large number of medications have been tested, there are only two ﬁrst-line
medications, primidone and propranolol,which is a situation that has not changed in approxi-
mately 30 years. Several recent reviewshave summarized the current pharmacotherapeutic
options for ET and the approach to the management of ET patients. Yet there remain a
number of important issues, both scientiﬁc and clinical, that have not been broached in
the literature and that have therapeutic implications. Objectives:To introduce several clin-
ical and scientiﬁc issues that have not formally entered the published literature on the
treatment of ET. Methods: In September 2011, materials for this article were gathered
during a literature search of PubMed using the following terms: ET, clinical, clinical trial,
treatment, medications, therapeutics. English-language articles were selected for further
review. Results: The paper focuses on several topics that have received scant or no dis-
cussion in the published literature on ET therapeutics. These topics are as follows: the
nature of the underlying disease pathophysiology, the presence of pathological hetero-
geneity, the complexity of cellular and neurochemical changes which may be underlying
this disorder, the presence of clinical heterogeneity, the selection of treatment endpoints,
the effects of diagnostic uncertainty, the presence of cognitive and psychiatric features in
ET, the identiﬁcation of possible modiﬁable risk factors, and the absence of any neuropro-
tective therapies. Conclusion:The author has identiﬁed several topics that have received
scant or no discussion in the published literature on ET therapeutics. Further discussion of
the issues raised here may lead to improvements in clinical trial methodologies as well as
facilitate the development of fresh approaches to pharmacotherapy.
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INTRODUCTION
Essential tremor (ET), a disease whose hallmark feature is action
tremor of the hands, is one of the most common neurological dis-
eases. It occurs in approximately 4.0% of individuals aged 40 years
and older (Dogu et al., 2003) and its prevalence continues to rise
with age, with prevalence estimates of 21.7% among persons aged
95 years and older (Louis et al., 2009c). The tremor is often pro-
gressive (Critchley, 1949) and patients may experience difﬁculties
performing basic daily activities (Busenbark et al., 1991; Bain et al.,
1994; Louis et al., 2001), thereby impairing quality of life (Troster
et al., 2005). In addition to action tremor, patients may also have
intention tremor (Louis et al., 2009b), rest tremor (Cohen et al.,
2003), and other motor signs, including ataxia (Singer et al., 1994).
More than 90% of patients who seek medical care report disabil-
ity (Louis et al., 2001), and severely affected end-stage patients
are unable to feed or dress themselves. Between 15 and 25% of
patients are forced to retire prematurely, and 60% choose not to
apply for a job or promotion because of uncontrollable shak-
ing (Rautakorpi, 1978; Bain et al., 1994). There have been few
studies of mortality; however, the one prospective study that also
enrolled a control group reported a 45% increased risk of mortality
(Louis et al., 2007b), suggesting that ET could be a disease of both
increased morbidity and mortality. In addition to the presence of
motor signs, a recent literature has documented the presence of
non-motor manifestations as well. These include cognitive deﬁcits
and dementia (Troster et al., 2002; Benito-Leon et al., 2006a,b;
Bermejo-Pareja et al., 2007), personality traits and depression
(Chatterjee et al., 2004; Lorenz et al., 2006; Louis et al., 2007d).
The pharmacological treatment of ET is not optimal (Gironell,
2007).Althoughmanymedications have been tested, there are only
two ﬁrst-line medications, primidone and propranolol (Table 1;
Zesiewicz et al., 2002, 2005; Benito-Leon and Louis, 2006, 2007),
which is a situation that has not changed in approximately 30 years
(Winkler and Young, 1971; Chakrabarti and Pearce, 1981). Fur-
thermore, medications are often considered to be effective in only
50% of patients with this disease (Thanvi et al., 2006). Even when
effective, medications rarely reduce the tremor to asymptomatic
levels (Gironell et al., 1999) and they are often associatedwith trou-
blesome side effects (e.g., somnolence, depression), so that many
patients decide to discontinue them. For example, in one clinical
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Table 1 | Medications that have been evaluated in the treatment of ET
(Zesiewicz et al., 2005; Benito-Leon and Louis, 2007; Lyons and
Pahwa, 2008b; Deuschl et al., 2011).
First-line medications Primidone
Propranolol
Additional medications Acetazolamide
Alprazolam
Atenolol
Botulinum toxin
Clonazepam
Clozapine
3,4-diaminopyridine
Ethanol
Gabapentin
Isoniazid
Levetiracetam
Nadolol
Nimodipine
Octanol
Olanzapine
Oxcarbazepine
Phenobarbital
Pindolol
Pregabalin
Sodium oxybate
Sotalol
Tiagabine
Topiramate
Trazodone
Zonegran
trial of primidone, a ﬁrst-line medication, 7 of 11 patients (63%)
chose not to take the medication when the trial ended (Sasso et al.,
1990). In a recent survey of more than 500 ET patients, nearly one
in three had stopped taking medications for their tremor and a
nearly identical proportion of ET patients with severe tremor also
had discontinued medications (Louis et al., 2010). In sum, there is
a sizable population of ETpatients,many of whomhave functional
disability and impaired quality of life, who remain untreated. In
recent years, a limited number of pharmacologically unresponsive
patients have turned to deep-brain stimulation (DBS) and other
surgeries to provide relief (Hubble et al., 1997; Hariz et al., 1998;
Schuurman et al., 2000; Kondziolka et al., 2008). Several recent
reviews have provided detailed accounts of the current pharma-
cotherapeutic options for ET (Zesiewicz et al., 2005; Benito-Leon
and Louis, 2007; Lyons and Pahwa, 2008b; Deuschl et al., 2011).
The goal of this paper is not to duplicate those reviews, but rather,
to raise a number of clinical and scientiﬁc issues that have yet to
formally enter the published literature on the treatment of ET and,
in doing so, to further stimulate dialog in this ﬁeld.
METHODS
In September 2011,materials for this articlewere gathered during a
literature search of PubMed using the following terms: ET, clinical,
clinical trial, treatment, medications, therapeutics. Relevant articles
published before September 2011 were retrieved and only English-
language articles were selected for further review. Based on this
review, the author identiﬁed several topics that have received scant
or no discussion in the published literature on ET therapeutics.
RESULTS
Based on the literature review, the author identiﬁed several topics
that have received scant or no discussion in the published literature
on ET therapeutics.
TOPIC 1: WHAT IS THE NATURE OF THE DISEASE WE ARE TREATING?
While appraising the current state of pharmacotherapy, it is impor-
tant the one takes into consideration the nature of the underlying
disease process and its pathophysiological underpinnings. Recent
data, emerging from controlled studies of human postmortem tis-
sue, indicate the presence of degenerative changes in ET brains
(Louis et al., 2005, 2006a,b, 2007c; Louis and Vonsattel, 2007) In
the large majority of cases, these changes occurred in the cerebel-
lum (Louis et al., 2006a,b, 2007c; Louis andVonsattel, 2007). These
changes included swellings of Purkinje cell axons and dendrites,
signiﬁcant (approximately 30–40%) death of Purkinje cells, het-
erotopic displacement of Purkinje cells (Kuo et al., 2011), remodel-
ing of neighboring neurons (e.g., Basket cells; Louis andVonsattel,
2007; Louis et al., 2007c;Axelrad et al., 2008; Louis, 2009; Erickson-
Davis et al., 2010), and, in some cases,more extensive degenerative
changes in the cerebellum (Louis et al., 2006a). Many though
not all of these changes have been observed to varying degrees
in the brains of patients with spinocerebellar ataxias (SCAs), a
group of diseases that, like ET, are strongly familial, progressive,
and associated with intention tremor and ataxia (Koeppen, 2005).
These postmortem data, along with the clinical picture of a disease
process with insidious onset and progressive nature indicate that
the disease is probably neurodegenerative in nature (Louis, 2009;
Bermejo-Pareja, 2011).
Given a situation in which the root cause of the disease seems
likely to be a progressive degeneration of neuronal tissue, what
can one realistically expect of medications? The pharmacologi-
cal treatment of the neurodegenerative diseases [e.g., Alzheimer’s
disease (AD), amyotrophic lateral sclerosis (ALS)] is, unfortu-
nately, very limited (Henriksen et al., 2006; Klafki et al., 2006;
Karran and Palmer, 2007; Zoccolella et al., 2009). There have
been a small number of successes, but these are the exceptions
rather than the rule. One is that of Parkinson’s disease (PD), in
which the pharmacological replacement of brain dopamine pro-
vides temporary relief of some but not all motor symptoms (Diaz
and Waters, 2009), although this relief is time-limited, and the
treatment of PD-related cognitive decline has not been successful.
Another is Huntington’s disease (HD), in which pharmacolog-
ical manipulation of brain dopamine production, release and
post-synaptic binding provides some relief from chorea (Cardoso,
2009), although not for the progressive cognitive and personal-
ity changes or incoordination that accompany this relentlessly
progressive disorder.
Perhaps more pertinent for ET is the SCAs, for reasons noted
above. The symptomatic treatment of the SCAs is also very limited.
The most prominent feature, ataxia, is very difﬁcult to manage;
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there are no clearly effective treatments available, and no FDA-
approved medications for this symptom (Fogel and Perlman,
2006). It is within this broader context that one must concep-
tualize the treatment of ET and the challenging task of developing
effective pharmacotherapeutic options.
While considering pathophysiology, there is one other issue
that merits attention, and this is the issue of pathological het-
erogeneity. Although the majority of ET cases have degenera-
tive changes in the cerebellum, this is not true of all cases. In
some postmortem studies, a smaller sub-set has been reported to
have other degenerative changes in the form of brainstem Lewy
bodies (Louis and Vonsattel, 2007; Louis et al., 2007c). Hence,
postmortem studies indicate the likely presence of pathological
heterogeneity, with several different tissue-based subtypes of ET
having been identiﬁed thus far (Louis and Vonsattel, 2007; Louis
et al., 2007c). These postmortem observations are likely to be
relevant to the treatment of ET. A reoccurring ﬁnding in many
pharmacotherapeutic trials of ET is that the response to medica-
tion is usually mixed, with approximately one-third to one-half
of the patients showing a moderate degree of tremor reduc-
tion and the other patients demonstrating little or no response
at all (Gironell et al., 1999). One possibility is that this hetero-
geneity of clinical response is a marker of different underlying
disease mechanisms in subsets of patients. If ET is a heteroge-
neous family of diseases rather than a single clinical–pathological
entity (Louis, 2009), then one set of therapies is not likely to
be effective in all cases. In other words, therapeutic response
phenotype is likely to be dependent on underlying pathological
subtype.
TOPIC 2: DO WE KNOW HOW CURRENT TREATMENTS ARE WORKING?
Clinical updates on tremor generally divide treatments into ﬁrst-
line vs. second-line medications, with the former having more
demonstrable efﬁcacy (Table 1; Zesiewicz et al., 2005; Benito-
Leon and Louis, 2007; Lyons and Pahwa, 2008b). Long lists of
second-line medications provide a catalog of drugs that have
been tried and have either failed or only been partly successful
(Zesiewicz et al., 2005; Benito-Leon and Louis, 2007; Lyons and
Pahwa, 2008b). A mixture of possible mechanisms of action is
brieﬂy noted for some of the listed medications and for others,
none at all. What is missing, however, is a broad and unify-
ing discussion of the probable mechanism of action of these
medications.
Aside from the beta blockers,whose mechanism of action in ET
is related to antagonism of peripheral beta-adrenergic receptors in
muscle, a unifying feature of the large majority of medications
that are used in the treatment of ET (e.g., primidone, phenobar-
bital, gabapentin, topiramate, benzodiazepines, sodium oxybate,
ethanol, and octanol) is that they enhance gamma amino-butyric
acid (GABA)-ergic tone in the central nervous system (Rincon
and Louis, 2005). In addition to the observed reduction in Purk-
inje cells in ET (Louis et al., 2007c; Axelrad et al., 2008; Shill
et al., 2008), low cerebrospinal ﬂuid GABA levels have also been
observed in patients with ET (Mally and Baranyi, 1994; Mally
et al., 1996). The neurotransmitter of Purkinje cells is GABA, and
the effect of the cerebellum through Purkinje cell output is mod-
ulatory or inhibitory. A decrease in the number or function of
Purkinje cells would result in reduced inhibitory cerebellar out-
ﬂow and over-excitation. DBS is an effective surgical treatment for
ET (Schuurman et al., 2000; Pahwa et al., 2001; Kluger et al., 2009);
although its mechanism of action is not fully known, a number
of possibilities have been discussed (Ushe et al., 2004), and one
might be an alteration in abnormal cerebellar–thalamic outﬂow,
which is involved not only in the generation and propagation of
ET tremor but more broadly of rest tremor in PD (Helmich et al.,
2011).
While attempts to increase central GABA-ergic tone have
resulted in limited success in the treatment of ET, a more sophisti-
cated approach to this problem has yet to be devised. Although
GABA is the inhibitory transmitter of Purkinje cells, it is also
the transmitter of other neurons in the cerebellum, including the
Golgi cells and Basket cells. Basket cells are GABA-ergic inhibitory
interneurons found in the molecular layer; they send out axonal
collaterals to form a pericellular basket around the Purkinje cell
body (Erickson-Davis et al., 2010). Recent study has found that
basket cell processes are increased in ET, perhaps as a secondary
remodeling response to Purkinje cell loss (Erickson-Davis et al.,
2010). It is not clear how the peripheral administration of drugs
that grossly elevate GABA-ergic tone inﬂuences this complex,
multi-neuronal, GABA-ergic network in the cerebellum. Current
experience (Thompson et al., 1984; Pahwa et al., 1998; Ondo et al.,
2006; Zesiewicz et al., 2007), however, suggests that the effects
of simply increasing GABA-ergic tone are mixed and varied. The
issue deserves more critical scrutiny.
TOPIC 3: THE “ONE SIZE FITS ALL” APPROACH: IS IT TIME TO MOVE
BEYOND THIS?
As noted above, recent postmortem studies suggest an underly-
ing mechanistic heterogeneity for ET. One may approach the issue
of heterogeneity from a clinical vantage point as well (Table 2).
Among clinicians and clinical trialists, the traditional approach
to the treatment of ET has largely been to regard ET patients as
a single, homogeneous group. Perhaps the only exception is the
occasional separationof patientswithhead tremor fromthosewith
upper limb tremor (Obwegeser et al., 2000; Song et al., 2008). The
“one size ﬁts all” approach is potentially problematic for several
reasons. For example, this approach likely increases the occur-
rence of Type II errors in clinical trials (i.e., failing to reject the
null hypothesis when there is a treatment effect). In clinical trials
Table 2 | Sources of clinical and pharmacological heterogeneity in ET.
Feature Comment
Head tremor May be less responsive to medications than arm tremor
(Song et al., 2008)
Voice tremor May be less responsive to medications than arm tremor
(Lyons and Pahwa, 2008a)
De novo vs.
previously
treated
Previously treated patients may be less responsive to
medications, although no data directly address this issue
Short duration vs.
long duration ET
Longer duration could be less responsive to
medications, although no data directly address this issue
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in ET, one rarely distinguishes between de novo patients and previ-
ously treated patients; the two are generally lumped together and
data are not presented on the mix of these cases entering the trial.
Previously treated patients are generally self-selected to have been
non-responsive to multiple previously tried medications and they
are not ideal candidates for the testing of new therapies. Although
this group of cases is often very motivated to ﬁnd a treatment that
is effective for them, their enrollment may falsely lead to the rejec-
tion of therapies that are potentially efﬁcacious. At the very least,
there is a need for clinical trials to report the number of de novo
vs. previously treated patients and to analyze results separately for
these two groups. An additional consideration is that it is impor-
tant to distinguish between short-term response and longer-term
response in clinical trials.
Another problem with the “one size ﬁts all” approach is that
patients may have a wide range of underlying disease durations.
Longer duration disease in ET is associatedwith additional signs of
cerebellar degeneration, including intention tremor (Louis et al.,
2009b) and ataxic gait (Stolze et al., 2001), suggesting that long
duration disease could be accompanied by more degenerative
changes in the cerebellum and hence, a different brain substratum
on which to apply pharmacotherapeutic interventions. In other
words, the degree to which the underlying pathophysiological (i.e.,
tissue-based) changes have advanced is likely to inﬂuence themag-
nitude of therapeutic response. For example, in PD, advances in
underlying Lewy body pathology are the likely underpinnings for
end-stage, levodopa refractory disease (i.e., loss of the levodopa
motor response; Apaydin et al., 2002).
TOPIC 4: MAKING SENSE OF THE DATA: MULTIPLE TREATMENT
EFFICACY ENDPOINTS
To the new comer, making sense of the data in various treatment
trials can be challenging. One issue is that clinical trials often uti-
lize a confusingmélange of treatment endpoints and, furthermore,
they present data in which therapeutic efﬁcacy is found for some
endpoints yet not for others. These endpoints may be broadly
divided into four types: patient’s subjective self-ratings, clinician’s
ratings, performance-based tests of function, and accelerometry
(Table 3). While the ﬁrst of these is subjective, the remaining
three are objective, making them preferable. Accelerometry is the
most precise and the most objective endpoint, yet the clinical cor-
relates of accelerometric-measured changes can be unclear. For
example, does a 25% reduction in tremor amplitude, as measured
by accelerometry, necessarily translate into a clinically relevant
functional change for the patient? What relative change as well
as absolute ﬁnal value is indicative of clinically meaningful phar-
macotherapeutic efﬁcacy? Clinician’s ratings, which by their very
nature are clinically grounded,generate values that are ordinal (i.e.,
3> 2> 1) but the difference between any two values is not neces-
sarily the same (i.e., they are not interval values like the degrees on
a thermometer). Also, they may not be sensitive to small changes.
Hence, inmanyways, performance-based tests of function provide
the best alternative. First, they are objective assessments of func-
tion and second, they offer clinically and functionally relevant
assessments of tremor. The ordinal rather than interval nature of
the values that are used is a limitation.
The current state of affairs is that many tremor trials use a small
number of these endpoints while others present data on all four.
Performance-based tests are not always used. Many trials do not
specify primary vs. secondary endpoints, so that the interpretation
of the results, which is often mixed because the various endpoints
assess different properties of tremor, is left to the reader. As a
community, clinical trialists in ET should agree on the optimal
methods for the uniform presentation of data. Indeed, it would be
important to derive a core set of measures to be performed in each
treatment trial of ET, so that pooling of data can be performed and
more reproducible results for treatment of ET can be reported.
TOPIC 5: ARE WE OVERLOOKING IMPORTANT TREATMENT
ENDPOINTS?
As noted above, one issue is understanding the assortment of end-
points that are currently being used in clinical trials. Another issue
is whether we are identifying and routinely evaluating all of the
potentially important endpoints. Each of the endpoints discussed
above assessed tremor severity. Perhaps an equally important issue
in ET is embarrassment. Embarrassment is a common feature in
ET. In a recent study (Louis and Rios, 2009), 58.2% of ET cases
seen in a clinical setting reported embarrassment. Embarrass-
ment is not only prevalent, but a major motivator for treatment
(Louis and Rios, 2009). Anecdotal experience indicates that it is
Table 3 |Treatment efficacy endpoints in ET.
Advantages Disadvantages
Patient’s subjective self-rating Reﬂects the patient’s own perception Completely subjective
Clinically meaningful Difﬁcult to quantify
Clinician’s rating Objective Does not generate interval data
Clinically grounded May not be sensitive to small changes
Incorporates clinical experience
Easily administered
Performance-based test of function Objective Does not generate interval data
Assesses functionally relevant items
Easily administered
Accelerometry Objective Clinical meaning is intrinsically unclear
Precise More difﬁcult to administer
Generates interval data
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one of the major reasons why patients seek treatment (Benito-
Leon and Louis, 2007) and the study in New York found that the
experience of embarrassment nearly doubled the odds of using
tremormedication (Louis andRios, 2009). Despite its importance,
embarrassment is not routinely assessed in clinical trials nor is
decline in embarrassment reported as a treatment endpoint. An
embarrassment questionnaire for ET patients has recently been
developed and validated (Traub et al., 2010); the questionnaire
could be used in clinical trials and clinical settings to assess changes
in level of embarrassment.
Another issue is quality of life. This issue has only come to the
forefront in recent surgical trials (Troster et al., 1999; Hariz et al.,
2002, 2008) and the development of an ET-speciﬁc instrument
(Troster et al., 2005) paves the way for future examination of this
issue.
TOPIC 6: DIAGNOSTIC MISCLASSIFICATION: A LIKELY SOURCE FOR
LOW PHARMACOLOGICAL RESPONSE RATES
As noted above, one potential source of low pharmacological
responsiveness in clinical trials is the enrollment of previously
treated rather than de novo patients. Another source, both in clin-
ical trials and in routine clinical practice, is diagnostic misclassiﬁ-
cation. Studies in both England and the United States have shown
that 30–50% of ET cases are misdiagnosed (i.e., they frequently
have other diseases such as PD or dystonia; Table 4; Schrag et al.,
2000; Jain et al., 2006). The explanation is not clear yet one con-
tributor may be that ET is often still regarded as a single, relatively
featureless, neurologic sign. This is not the case. Among a host
of other characteristics, the relative severity of different tremor
types (kinetic more severe than postural; Brennan et al., 2002),
the favored sites of anatomical involvement (arm more often than
head, head more often than jaw; Louis et al., 2003), and the typi-
cal direction of spread over time (from arms to head rather than
the converse; Louis, 2009) are distinctive, adding a degree of sub-
tlety and complexity to the recognition and diagnosis of a disorder
that is often viewed as relatively ordinary and featureless (Louis,
2009). In addition, the presence of other elements (e.g., postural
tremor predominated by ﬁnger rather than wrist ﬂexion, pos-
tural tremor manifesting mainly as thumb-ﬂexion, re-emergent
nature of postural tremor, dystonic posturing in tremulous limbs),
which suggest the alternative diagnoses of PD or dystonia, are
often not appreciated. Perhaps owing to a lack of familiarity with
these features,misdiagnosis is exceedingly common. Regardless of
the root cause, this high level of misdiagnosis suggests that ET,
aside from being one of the most common neurological disorders,
might be one of the most commonly misdiagnosed neurological
disorders, with over application of the diagnosis being the main
Table 4 | Essential tremor: common misdiagnoses.
Study Jain et al. (2006) Schrag et al. (2000)
True diagnoses
of “ET”
patients
Parkinson’s disease Dystonic tremor
Dystonic tremor Neuropathic tremor
Myoclonus dystonia Drug-induced tremor
Primary writing tremor Post-traumatic tremor
Enhanced physiological tremor
problem. Consensus criteria (Deuschl et al., 1998) were proposed
for ET more than a decade ago; despite this, a number of different
diagnostic schemes for ET have been proposed and are in common
use (Louis et al., 1997; Deuschl et al., 1998; Bain et al., 2000; Elble,
2000).
Another contributor to misdiagnosis is the ambiguity perpet-
uated by current diagnostic codes. Although there is an Interna-
tional Classiﬁcation of Diseases (ICD) code for tremor (333.1),
there is no speciﬁc ICD code for ET (Louis et al., 2007a). There is
no unique code for several common tremor conditions, including
enhanced physiological tremor, psychogenic tremor, orthostatic
tremor, and drug-induced tremor. As a result, there is a tendency
to lump a wide variety of different types of action tremor together.
Given the very high rate of diagnostic misclassiﬁcation, which is
further exacerbated by ambiguity in the current ICD coding sys-
tem, clinicians should be asking themselves whether they have the
correct diagnosis before embarking on a treatment course for ET.
Diagnostic misclassiﬁcation is likely to be a source of low pharma-
cological response. If a clinician is treating PD or dystonia cases
with ET medications, these “ET cases” are not likely to respond to
these medications.
TOPIC 7: PERSONALITY CHARACTERISTICS IN ET: COULD THESE
INFLUENCE TREATMENT?
Certain personality characteristics have been linked with neu-
rological disorders. A rigid and introverted personality type has
been suggested as possibly associated with PD, and PD patients
have been described as industrious, punctual, inﬂexible, cautious,
and lacking in novelty seeking (Menza, 2000; Ishihara and Brayne,
2006; Macias et al., 2008). Whether and to what extent such traits
are pre-morbid or disease-associated is not clear. HD patients, on
the other hand, are often disinhibited and engage in more risk-
taking behaviors (Stout et al., 2001). The neural basis for these
observations is unclear but could involve alterations within neu-
rotransmitter systems (e.g., dopamine). Personality changes have
also been noted in patients with spinocerebellar ataxia as well
(Leroi et al., 2002). A tendency for certain personality features has
been noted in ET. A study in New York (Chatterjee et al., 2004)
reported higher harm avoidance scores in ET patients than con-
trols. People who are more harm avoidant tend to be worrying,
pessimistic, fearful, and doubtful rather than relaxed, optimistic,
bold, and conﬁdent. Perhaps similarly, a study in Germany, which
used a standardized personality inventory,noted that their patients
with ET were kinder, more tender-minded, and less aggressive
when compared with population controls (Lorenz et al., 2006),
although the two studies used different personality inventories,
making comparisons difﬁculty. Whether these features are pre-
morbid, an early sign of morbidity, a later sign of morbidity, or a
response to morbidity is not known. Regardless, the presence of
personality features in ET, or any other disease, could have reper-
cussions in terms of treatment, inﬂuencing the types of health care
choices that patients make. For example, it has been pointed out
that although ET is many times more prevalent than PD, the num-
ber of ET patients who are seriously impaired by their tremor who
reach a DBS clinic for consideration of surgery is curiously very
small, and perhaps as few as one-third of those being evaluated for
surgery for PD (Young, 2002). A number of factors could underlie
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this observation. One is the slow rate at which ET develops and
the tendency for patients with severe ET to modify and then grad-
ually give up certain activities, thereby accommodating to some
extent to their illness. Another explanation, however, may be a
disease-related tendency toward harm avoidant behavior. Further
evaluation of this issue is needed, but it is possible that the fea-
tures of the disease itself inﬂuence the manner in which treatment
is approached and accepted.
TOPIC 8: COGNITIVE IMPAIRMENT IN ET: WHAT ARE THE THERAPEUTIC
IMPLICATIONS?
Many of the neurodegenerative diseases (e.g., AD, PD, HD) mani-
fest as mixed cognitive–motor disorders. In these disorders, the
underlying anatomic pathologies are widespread in the brain,
involving both motor and cognitive areas. Disorders such as PD
that canonically were deﬁned as purely motor, are now known to
have cognitive and psychiatric manifestations (Stern et al., 1993).
Also, an individual with one of these disorders is probably at
increased risk of developing another (the concept of increased
tissue vulnerability, with examples including the increased co-
occurrence in certain individuals of PD and AD, Mayeux et al.,
1988; ET and PD, Tan et al., 2008; Benito-Leon et al., 2009; ET
and AD, Benito-Leon et al., 2006a; Bermejo-Pareja et al., 2007;
Thawani et al., 2009), so that these disorders can co-occur in the
same individual. There is an emerging literature documenting cog-
nitive impairment and dementia in ET patients (Gasparini et al.,
2001; Lombardi et al., 2001; Troster et al., 2002; Benito-Leon et al.,
2006a,b; Bermejo-Pareja et al., 2007; Thawani et al., 2009).
What are the clinical implications for ET? First, the presence of
cognitive impairment likely limits the maximum tolerable dose of
medications, and especially those medications with known cog-
nitive side effects. Hence, the maximum attainable dose is lower
than in patients without cognitive impairment or dementia.
Second, these cognitive problems, in their own right, should
probably be a target for therapeutic intervention.Clinicians should
begin to assess whether the cognitive problems in their ET patients
reﬂect a diagnosis of mild cognitive impairment or dementia
rather than dismissing the problem as merely due to old age. If
a diagnosis of dementia is assigned, then what are the best treat-
ments for ET-related dementia? To some extent, this depends on
the underlying nature of the dementiawhich occurs in ETpatients.
There are few data, yet clinical–epidemiological studies suggest
that it is AD (Benito-Leon et al., 2006a; Bermejo-Pareja et al.,
2007; Thawani et al., 2009). The use of AD medications has not
been formally explored in ET patients who have dementia.
TOPIC 9: NEUROPROTECTIVE THERAPY AND MODIFIABLE RISK
FACTORS IN ET: BEGINNING A DIALOG
The exploration of new medications for ET is focused exclu-
sively on symptomatic therapies (Lee et al., 2003; Shill et al., 2004;
Bushara et al., 2005; Gironell et al., 2006, 2008; Ondo et al., 2006;
Handforth et al., 2009). With evidence from clinical, neuroimag-
ing, and postmortem studies indicating that ET is likely to be a
neurodegenerative disease (Louis, 2009), several questions arise.
First, are there ways in which one can alter and slow the progres-
sion of the disease, and second, is there a mechanism to prevent
the onset of disease?
Exploration of neuroprotective therapies has been ongoing in
PD (Kieburtz and Ravina, 2007; Voss and Ravina, 2008; Hart
et al., 2009) and HD (Emerich, 2001; Hersch and Rosas, 2008)
for decades yet there have been no such trials in ET. The cellular
changes that underlie ET are just now beginning to be elucidated
and new knowledge should provide insights into the molecular
mechanisms that underlie this disorder. Such insights could form
the biologically based rationale for testing neuroprotective agents.
Modiﬁable risk factors have been identiﬁed for numerous neu-
rological and systemic diseases (Booya et al., 2005; Reynolds et al.,
2007; Di Pauli et al., 2008; Rains, 2008; Arima, 2009; Kotseva et al.,
2009; Ovbiagele, 2010). These factors are extremely important
because they form the backbone of primary prevention. There
has been little discussion of these in ET. In a recent prospec-
tive, population-based study in central Spain (Louis et al., 2009a),
lifetime ethanol consumption was assessed at baseline in 3,285
elderly participants, of whom 76 developed incident ET by follow-
up. With each higher drink-year quartile, the risk of incident ET
increased an average of 23%, and the highest quartile was associ-
atedwith twice the risk of incident ET. Ethanol is awell-established
cerebellar toxin, resulting in Purkinje cell loss (Karhunen et al.,
1994; Ramadoss et al., 2007; Dlugos, 2008). As noted above, recent
postmortem studies have found pathological changes, including
Purkinje cell loss, in the cerebellum in ET (Louis et al., 2007c;
Axelrad et al., 2008; Shill et al., 2008) Ethanol, which is often
used for symptomatic relief of ET (Benito-Leon and Louis, 2007),
could be a continued source of underlying cerebellar neurotoxic-
ity in patients who already manifest this disease. In sum, ethanol
consumption might be a modiﬁable risk factor in ET and mini-
mization of ethanol consumption in ET patients could alter the
course of progression. Furthermore, minimization in at-risk indi-
viduals could delay the onset of the illness. Further studies are
clearly needed, but these initial data at least open the possibility
that disease course could be modiﬁed in ET.
One study found that baseline heavy cigaret smoking was asso-
ciated with a lower risk of incident ET (Benito-Leon et al., 2008).
The adverse health effects associated with smoking; however, do
not make this a practical approach to lowering risk of ET.
DISCUSSION
In this review, a number of clinical and scientiﬁc issues were raised
that are relevant to the treatment of ET. These include issues of
underlying disease pathophysiology, the presence of pathological
heterogeneity, the complexity of the cellular and neurochemical
changes which may be underlying this disorder, the presence of
clinical heterogeneity, selection of treatment endpoints, the effects
of diagnostic uncertainty, the presence of cognitive and psychiatric
aspects to the disease, and the identiﬁcation of possible modiﬁable
risk factors, and the absence of any neuroprotective therapies. It is
hoped that further discussion of these issues will lead to improve-
ments in clinical trial methodologies and clinical practice, as well
as facilitate the development of newer therapies for this common
neurological disease.
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